MyFinsight
Home
Blog
About
Short-term investments
$218,437K
(77.70%↑ Y/Y)
Cash and cash
equivalents
$154,682K
(37.17%↑ Y/Y)
Prepaid expenses and
other current assets
$21,054K
(45.58%↑ Y/Y)
Total current assets
$394,173K
(57.58%↑ Y/Y)
Right of use assets -
operating leases
$370K
(335.29%↑ Y/Y)
Other assets
$134K
(-72.03%↓ Y/Y)
Deferred offering costs
$41K
Total assets
$394,718K
(46.46%↑ Y/Y)
Total liabilities and
stockholders' equity
$394,718K
(46.46%↑ Y/Y)
Total stockholders'
equity
$366,841K
(46.81%↑ Y/Y)
Total liabilities
$27,877K
(41.97%↑ Y/Y)
Accumulated deficit
-$497,854K
(-49.00%↓ Y/Y)
Accumulated other
comprehensive income (loss)
-$267K
(-1383.33%↓ Y/Y)
Additional paid-in capital
$864,957K
(48.11%↑ Y/Y)
Total current
liabilities
$27,844K
(41.80%↑ Y/Y)
Operating lease
liabilities, net of current...
$33K
Common stock 0.0001 par
value, 200,000,000...
$5K
(25.00%↑ Y/Y)
Accrued expenses
$25,309K
(63.52%↑ Y/Y)
Accounts payable
$2,217K
(-45.39%↓ Y/Y)
Operating lease
liabilities
$318K
(224.49%↑ Y/Y)
Back
Back
Balance Sheet
ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc. (AVBP)
source: myfinsight.com